Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guoli Lin

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Biomed Research International|June 29, 2017
TDF Monotherapy Is Effective Regardless of Prior Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patients in ChinaMingxing Huang, Guoli Lin, Hong Shi, et al.
Hepatology International|July 24, 2015
Real-life practice of antiviral therapy and disease patterns of patients with chronic hepatitis B: a single-center retrospective observation studyYusheng Jie, Xiangyong Li, Guoli Lin, et al.
International Immunopharmacology|September 20, 2025
TRIM21 exacerbates hypoxia-induced cardiomyocyte Pyroptosis through GSDMD ubiquitination in post-myocardial infarction heart failureGuoli Lin, Juying Li, Yihao Huang, et al.
International Journal of Clinical and Experimental Medicine|March 19, 2015
Comparison of the efficacy of tenofovir disoproxil fumarate and entecavir for initial treatment of patient with chronic hepatitis B in ChinaMingxing Huang, Yusheng Jie, Hong Shi, et al.
Clinical Drug Investigation|March 20, 2016
Long-Term Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleos(t)ide-Experienced Chronic Hepatitis B PatientsMingxing Huang, Yusheng Jie, Guoli Lin, et al.
Plos One|June 2, 2017
Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosisZhanyi Li, Bingliang Lin, Guoli Lin, et al.
Biomed Research International|August 29, 2020
Prediction Model of HBsAg Seroclearance in Patients with Chronic HBV InfectionJing Cao, Jiao Gong, Christ-Jonathan Tsia Hin Fong, et al.
Annals of Palliative Medicine|December 24, 2019
Barriers to hepatitis C virus treatment in Guangdong ProvinceXiaohua Yang, Zhen Xu, Yongyu Mei, et al.
Biomed Research International|November 23, 2017
Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected PatientsZhanyi Li, Ying Liu, Ying Zhang, et al.
International Journal of Clinical and Experimental Medicine|February 18, 2016
Optimized combination therapies with adefovir dipivoxil (ADV) and lamivudine, telbivudine, or entecavir may be effective for chronic hepatitis B patients with a suboptimal response to ADV monotherapyXiangyong Li, Yusheng Jie, Xu You, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Biomed Research International|June 29, 2017
TDF Monotherapy Is Effective Regardless of Prior Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patients in ChinaMingxing Huang, Guoli Lin, Hong Shi, et al.
Hepatology International|July 24, 2015
Real-life practice of antiviral therapy and disease patterns of patients with chronic hepatitis B: a single-center retrospective observation studyYusheng Jie, Xiangyong Li, Guoli Lin, et al.
International Immunopharmacology|September 20, 2025
TRIM21 exacerbates hypoxia-induced cardiomyocyte Pyroptosis through GSDMD ubiquitination in post-myocardial infarction heart failureGuoli Lin, Juying Li, Yihao Huang, et al.
International Journal of Clinical and Experimental Medicine|March 19, 2015
Comparison of the efficacy of tenofovir disoproxil fumarate and entecavir for initial treatment of patient with chronic hepatitis B in ChinaMingxing Huang, Yusheng Jie, Hong Shi, et al.
Clinical Drug Investigation|March 20, 2016
Long-Term Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleos(t)ide-Experienced Chronic Hepatitis B PatientsMingxing Huang, Yusheng Jie, Guoli Lin, et al.
Plos One|June 2, 2017
Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosisZhanyi Li, Bingliang Lin, Guoli Lin, et al.
Biomed Research International|August 29, 2020
Prediction Model of HBsAg Seroclearance in Patients with Chronic HBV InfectionJing Cao, Jiao Gong, Christ-Jonathan Tsia Hin Fong, et al.
Annals of Palliative Medicine|December 24, 2019
Barriers to hepatitis C virus treatment in Guangdong ProvinceXiaohua Yang, Zhen Xu, Yongyu Mei, et al.
Biomed Research International|November 23, 2017
Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected PatientsZhanyi Li, Ying Liu, Ying Zhang, et al.
International Journal of Clinical and Experimental Medicine|February 18, 2016
Optimized combination therapies with adefovir dipivoxil (ADV) and lamivudine, telbivudine, or entecavir may be effective for chronic hepatitis B patients with a suboptimal response to ADV monotherapyXiangyong Li, Yusheng Jie, Xu You, et al.
Pageof 3